These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26214803)

  • 21. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
    Niederhauser N; Valmaggia C
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema.
    Noma H; Mimura T; Yasuda K; Shimura M
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1122-8. PubMed ID: 25634982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
    Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.
    Noma H; Funatsu H; Yamasaki M; Tsukamoto H; Mimura T; Sone T; Jian K; Sakamoto I; Nakano K; Yamashita H; Minamoto A; Mishima HK
    Am J Ophthalmol; 2005 Aug; 140(2):256-61. PubMed ID: 16086947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
    Noma H; Funatsu H; Mimura T; Harino S; Hori S
    Ophthalmology; 2009 Jan; 116(1):87-93. PubMed ID: 19118700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study.
    Zhao T; Lu Q; Tao Y; Liang XY; Wang K; Jiang YR
    Mol Vis; 2011 Apr; 17():1044-55. PubMed ID: 21552499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
    Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
    Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion.
    Koss MJ; Pfister M; Rothweiler F; Michaelis M; Cinatl J; Schubert R; Koch FH
    Acta Ophthalmol; 2012 Mar; 90(2):e98-e103. PubMed ID: 22066978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
    Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
    Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
    Fan C; Wang Y; Ji Q; Zhao B; Xie J
    Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.
    Song WT; Xia XB
    BMC Ophthalmol; 2015 Mar; 15():31. PubMed ID: 25881069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion.
    Park SP; Ahn JK; Mun GH
    Retina; 2010 Feb; 30(2):281-6. PubMed ID: 19881397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early bevacizumab treatment of central retinal vein occlusion.
    Ferrara DC; Koizumi H; Spaide RF
    Am J Ophthalmol; 2007 Dec; 144(6):864-71. PubMed ID: 17916320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
    Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
    Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy.
    Shchuko AG; Zlobin IV; Iureva TN; Ostanin AA; Chernykh ER; Mikhalevich IM
    Indian J Ophthalmol; 2015 Dec; 63(12):905-11. PubMed ID: 26862095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.